Insilico Medicine Investors
End-to-end generative AI-driven biotech companyWe are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical | Insilico /?
Investors
%20.jpg)
%20.jpg)
Connections from
%20.png)
Estimated Revenue:
US$35 million
Headquarters:
Massachusetts, Boston, New York, Deerfield, Pak Shek Kok, Hong Kong
Employee Number:
101-250
Number Of Exists:
11-50
Founded Date:
2014